Cidara Therapeutics, Inc. Q3 2025 Earnings Recap

Cidara Therapeutics reported strong progress in Q3 2025, marked by the early initiation of its Phase III ANCHOR trial for CD388 and receipt of Breakthrough Therapy Designation from the FDA.

Key Takeaways

• CD388 has entered Phase III development, expanding the potential patient population from 50 million to over 100 million in the U.S. by including healthy adults over 65.
• The ongoing ANCHOR trial, now over 50% enrolled, aims for completion in the Northern Hemisphere by December, leveraging a targeted participant group at high risk for influenza complications.
• Cidara secured a $45 million milestone payment from Johnson & Johnson for the trial initiation and was awarded $339 million from BARDA for expanded manufacturing and clinical development.
• CD388 has received Breakthrough Therapy Designation, promising expedited regulatory pathways and enhanced FDA guidance.
• The Phase IIb NAVIGATE study demonstrated a 76.1% protective efficacy against influenza, underpinning the drug's differentiated profile and bolstering confidence for Phase III success.